Related Experiment Video

Updated: May 28, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?

Rihab Nasr1, Hiba El Hajj, Youmna Kfoury

  • 1Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut 1107 2020, Lebanon. rn03@aub.edu.lb

Viruses
|October 14, 2011
PubMed

Insights

Targeted therapy for Adult T cell leukemia/lymphoma (ATL) shows promise. Combining zidovudine (AZT) with interferon-alpha (IFN) and arsenic trioxide effectively targets HTLV-I and the Tax protein, offering a path to cure ATL.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Adult T cell leukemia/lymphoma (ATL) is chemo-resistant.
  • HTLV-I retrovirus and viral oncoprotein Tax are key targets in ATL.
  • Current therapies show limited long-term efficacy.

Purpose of the Study:

  • To explore targeted therapies for ATL.
  • To investigate the mechanisms of action for zidovudine (AZT), interferon-alpha (IFN), and arsenic trioxide in ATL.
  • To evaluate the combination therapy's efficacy in preclinical models.

Main Methods:

  • Discussion of existing literature on AZT and IFN mechanisms.
  • Experimental induction of Tax proteolysis using IFN and arsenic trioxide.
  • Assessment of synergistic apoptosis induction in ATL cells.
  • Preclinical studies in mice targeting leukemia initiating cells.

Main Results:

  • IFN and arsenic trioxide induce Tax proteolysis and synergize to induce apoptosis.
  • Combination therapy cured Tax-driven ATL in mice by targeting leukemia initiating cells.
  • AZT and IFN combination significantly impacts ATL patient survival.
  • Mechanisms of action for antiviral and anti-Tax effects are discussed.

Conclusions:

  • Targeted degradation of Tax protein (arsenic/IFN) and viral replication inhibition (AZT) are crucial for curing ATL.
  • Therapeutic strategies should combine antiviral and anti-Tax approaches.
  • These findings provide a biological rationale for arsenic/IFN/AZT clinical success in ATL.
Keywords:
AZTHTLV-ITaxadult T cell leukemiaarsenic trioxideinterferon

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.